Current Status of the Research and Development of Diacylglycerol O-Acyltransferase 1 (DGAT1) Inhibitors: Miniperspective
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Diacylglycerol O-acyltransferase 1 (DGAT1) has recently become a highly interesting target for metabolic disorders as well as for hepatitis C virus (HCV). DGAT1 processes diacylglycerol to triglycerides in the final step of resynthesis for the absorption of fat across the intestine. Pharmaceutical companies have developed many novel inhibitors of DGAT1, several of which have reached the clinic. Proof of target engagement was achieved with the observation of reduced triglycerides upon treatment of humans with DGAT1 inhibitors; however, there were gastrointestinal adverse events such as nausea, diarrhea, and vomiting. These adverse events have been reported with multiple compounds and are possibly linked to the target because of the recent identification of a human cohort deficient in DGAT1. Clinical studies are continuing in a trial to treat patients with an orphan indication for familial chylomicronemia. The full potential of DGAT1 as a therapeutic target will need to overcome observed clinical adverse events, which are possibly mechanism based. The widespread use of DGAT1 inhibitors will ultimately depend upon a better understanding of how to improve the GI tolerability of these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Birch, A. M., Birtles, S., Buckett, L. K., Kemmitt, P. D., Smith, G. J., Smith, T. J. D., Turnbull, A. V., & Wang, S. J. Y. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801507v · Cited by 77
Cited by
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Walther, T. C., Chung, J., & Farese, R. V. (2017) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060608 · Cited by 762
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Structure and mechanism of human diacylglycerol O-acyltransferase 1
Wang, L., Qian, H., Nian, Y., Han, Y., Ren, Z., Zhang, H., Hu, L., Prasad, B. V. V., Laganowsky, A., Yan, N., et al. (2020) · Nature · doi:10.1038/s41586-020-2280-2 · Cited by 123
Futatsugi, K., Kung, D. W., Orr, S. T. M., Cabral, S., Hepworth, D., Aspnes, G., Bader, S., Bian, J., Boehm, M., Carpino, P. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01006 · Cited by 88
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Recent advances in triacylglycerol mobilization by the gut
Xiao, C., Stahel, P., Carreiro, A. L., Buhman, K. K., & Lewis, G. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.12.001 · Cited by 77
Meyers, C. D., Amer, A., Majumdar, T., & Chen, J. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.509 · Cited by 47
“Inhibition of DGAT1 may be a potential therapeutic target for treatment in which postprandial hypertriglyceridemia plays a pathophysiological role.(9) The novel DGAT1 inhibitor pradigastat is being developed for the treatment of FCS, a genetic disorder characterized by severe postprandial and fasting hypertriglyceride…”
BackgroundRocking the MBOAT: Structural insights into the membrane bound O-acyltransferase family
Coupland, C. E., Ansell, T. B., Sansom, M. S. P., & Siebold, C. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102589 · Cited by 22
Metadata
- Authors
- DeVita, R. J., & Pinto, S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-09-03
- Volume
- 56
- Issue
- 24
- Pages
- 9820-9825
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2409438593
- Cited by
- 101
- References
- 1
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.